Skip to content

A Pilot Study on Acupuncture as an Adjunctive Therapy for Intrahepatic Cholestasis of Pregnancy

A Pilot Study on Acupuncture as an Adjunctive Therapy for Intrahepatic Cholestasis of Pregnancy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000451
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic cholestasis of pregnancy (ICP)

Interventions

Treatment Group ?:Ursodeoxycholic Acid Capsules + S-adenosylmethionine (SAMe) combination therapy.
Treatment Group ?:Acupuncture point needling therapy in Traditional Chinese Medicine.
Treatment Group ?:Acupuncture point needling therapy in Traditional Chinese Medicine (TCM) combined with Western medicine therapy.

Sponsors

Wansheng Economic and Technological Development Zone People's Hospital, Chongqing, China
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Meeting the Western diagnostic criteria for ICP (elevated maternal fasting serum total bile acids (TBA) =10 µmol/L or non-fasting TBA =19 µmol/L, accompanied by unexplained pruritus and exclusion of other hepatobiliary diseases) . 2.Traditional Chinese Medicine (TCM) syndrome differentiation classified as liver-gallbladder damp-heat syndrome or blood deficiency with internal heat syndrome . 3.Age between 18 and 40 years . 4.Voluntary participation in the study, with written informed consent and compliance with follow-up assessments .

Exclusion criteria

Exclusion criteria: 1.Age 40 years. 2.Presence of systemic diseases (e.g., severe primary cardiovascular, hepatic, renal, hematopoietic disorders) or psychiatric disorders. 3.Hypersensitivity to the study drug. 4.Non-compliance with inclusion criteria, failure to adhere to prescribed treatment protocols, or incomplete data that compromises efficacy/safety evaluation. 5.For ICP-diagnosed patients: exclusion of secondary causes of elevated bile acids or liver dysfunction, such as cholelithiasis, hepatic tumors, viral hepatitis, or other hepatobiliary pathologies .

Design outcomes

Primary

MeasureTime frame
Severity of pruritus;Liver function and bile acids.;

Secondary

MeasureTime frame
Pregnancy outcome;

Countries

China

Contacts

Public ContactChen Yan

Wansheng Economic and Technological Development Zone People's Hospital, Chongqing, China

14965717@qq.com+86 136 3838 9949

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026